Douglas T Dieterich
- Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patientsDouglas T Dieterich
Gastroenterology and Hepatology, Cabrini Medical Center, New York University School of Medicine, New York, New York 10003, USA
J Infect Dis 185:S128-37. 2002..Ribavirin-associated hemolytic anemia is a potential problem in a patient population that is already susceptible to anemia but is manageable with recombinant human erythropoietin (epoetin alfa)...
- HBV plus HCV, HCV plus HIV, HBV plus HIVJames S Park
Division of Liver Diseases, Department of Medicine, Mount Sinai Medical Center, 5 East 98th Street, 11th Floor, New York, NY 10029, USA
Curr Gastroenterol Rep 8:67-74. 2006..The viral interactions between these viruses are complex, and their treatment may be challenging for clinicians...
- Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALTIra M Jacobson
Department of Gastroenterology and Hepatology, Weill Medical School of Cornell University, 450 East 69th Street, New York, NY 10021, USA
Am J Gastroenterol 99:1700-5. 2004..We sought to evaluate the efficacy of two doses of interferon alfa-2b (IFN) with ribavirin (RBV) in patients with normal ALT [correction]...
- Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1Mitesh R Patel
Department of Medicine, Mount Sinai School of Medicine, New York University, New York, USA
AIDS Read 16:164, 168-9; discussion 168-9. 2006..Reported here are 2 cases of HIV-HCV-coinfected genotype-1 patients who discontinued treatment early (after 3 and 8 weeks) because of adverse effects yet had a sustained virologic response with undetectable HCV viral loads at follow-up...
- Treatment of hepatitis C virus in HIV patients: a reviewNickolas Kontorinis
Department of Medicine, Mount Sinai Hospital, New York, NY 10029, USA
AIDS 19:S166-73. 2005..ART-associated hepatotoxicity has been demonstrated to occur more frequently in co-infected individuals and may be severe or fatal in some instances. Thus treatment of HCV has become a priority in HIV infected individuals...
- HIV/HCV coinfection in clinical practiceDouglas T Dieterich
Mount Sinai Hospital, Department of Medicine, New York, NY 10029, USA
J Int Assoc Physicians AIDS Care (Chic) 3:S4-14; quiz S16-7. 2004..The risk of HAART-related hepatotoxicity is greater in coinfected patients and therefore requires special consideration and close monitoring...
- Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infectionDaniel S Fierer
Divisions of Infectious Diseases, Mount Sinai School of Medicine, New York, NY, USA
Clin Infect Dis 56:1038-43. 2013....
- Evaluation of hepatitis C virus as a risk factor for HIV-associated neuroretinal disorderAndrea D Branch
Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
Clin Infect Dis 57:1618-25. 2013..We investigated associations between HCV and HIV-NRD and between HCV and single-nucleotide polymorphisms (SNPs) in the IL-10 receptor 1 (IL10R1) gene...
- Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfaDouglas T Dieterich
Mount Sinai School of Medicine, New York, New York 10029 6574, USA
Am J Gastroenterol 98:2491-9. 2003....
- Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirinNickolas Kontorinis
Department of Medicine, Mount Sinai Hospital, New York, NY, USA
Rev Gastroenterol Disord 4:S39-47. 2004..However, emerging data suggest that utilization of hematopoietic growth factors can provide a useful adjunct to treatment and optimize sustained virologic response rates...
- HIV and liver diseases: recent clinical advancesCem Cengiz
Division of Liver Diseases, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029, USA
Clin Liver Dis 9:647-66, vii. 2005..This article reviews various liver manifestations in patients who have HIV and the recent advances in diagnostic and therapeutic options...
- Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort studyDaniel S Fierer
Division of Infectious Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
J Infect Dis 198:683-6. 2008..No cause of liver damage other than acute HCV infection was identified. The specific pathways leading to periportal fibrosis in HIV-infected men with newly acquired HCV infection require investigation...
- Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis CSwati Chaudhari
New York University School of Medicine New York, New York, USA
Dig Dis Sci 49:1000-6. 2004..In these individuals, pancreatitis is often severe enough to warrant hospital admission, although symptoms resolve promptly after discontinuation of antiviral therapy...
- Special considerations and treatment of patients with HBV-HIV coinfectionDouglas T Dieterich
Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
Antivir Ther 12:H43-51. 2007..This review discusses the current status of treatment of hepatitis B in the setting of HIV infection. It describes emerging therapeutic strategies and addresses challenges in the treatment of coinfection...
- Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimenStephanie A Santos
Department of Medicine, Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA
Eur J Gastroenterol Hepatol 18:1247-53. 2006..Tenofovir disoproxil fumarate and emtricitabine show potent activity against wild-type and lamivudine-resistant hepatitis B virus...
- Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective studyAbraham Reichenberg
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
AIDS 19:S174-8. 2005....
- Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVRValérie Martel-Laferrière
Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
Clin Liver Dis 17:93-103. 2013..If the first combinations are leading to extremely high sustained virologic responses, the second ones offer hope that the era of pegylated-interferon will end soon...
- Hepatitis B therapies and antiviral resistance detection and managementGiselle Holness
Department of Medicine, Director of Outpatient Hepatology, Division of Liver Diseases, Mount Sinai School of Medicine, Annenberg 21 42, New York, NY 10029, USA
Expert Rev Gastroenterol Hepatol 3:693-9. 2009..It is important that clinicians monitor for therapeutic efficacy and resistance, so as to optimize the management of chronic HBV...
- Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir usersKathryn E Childs
Division of Infectious Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA
AIDS Res Hum Retroviruses 26:855-9. 2010..Because TDF is a potent and widely used antiretroviral drug, information about cofactors that may exacerbate its side effects is of significant clinical value...
- Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patientsP Wilfredo Canchis
Center for the Study of Hepatitis C, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
J Acquir Immune Defic Syndr 37:1125-31. 2004..09 cell/HPF) and monoinfected patients (0.45 +/- 0.08 cell/HPF). In conclusion, HIV coinfection is associated with fewer portal CD4 cells and increased lobular lymphocyte apoptosis that may impact on the natural history of HCV infection...
- Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitorsDouglas T Dieterich
Department of Medicine, Mt Sinai Medical Center, New York, New York 10029, USA
Clin Infect Dis 38:S80-9. 2004..3% of nevirapine-treated patients) of these elevations were asymptomatic. Symptomatic hepatic events were seen in 4.9% (3.2%-8.9%) of nevirapine-treated patients...
- Disease management--constructing optimal NRTI-based combinations: past, present, and futureDouglas T Dieterich
Department of Medicine, The Mount Sinai Medical Center, New York, NY, USA
MedGenMed 8:16. 2006
- Antiretroviral and anti-hepatitis C virus direct-acting antiviral-related hepatotoxicityHyosun Han
Department of Medicine, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, Annenberg 21 42, New York, NY 10029, USA
Clin Liver Dis 17:657-70, ix. 2013..The first-generation and newer HCV direct-acting antivirals are promising in coinfected patients, with minimal side effects and hepatotoxicity. ..
- Hepatitis C infection in HIV. Interview by Vicki GlaserDouglas T Dieterich
Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA
AIDS Patient Care STDS 18:127-30. 2004
- HIV and hepatitis B virus: options for managing coinfectionDouglas T Dieterich
Mt Sinai School of Medicine, New York, NY, USA
Top HIV Med 11:16-9. 2003..However, newer treatment options for chronic HBV infection increase the potential for successful management...
- Long-term complications of nucleoside reverse transcriptase inhibitor therapyDouglas T Dieterich
Department of Medicine, Mount Sinai School of Medicine, New York University, New York, USA
AIDS Read 13:176-84, 187. 2003..Mechanisms by which NRTIs may produce these effects are discussed, as are differential effects of agents in this class and management options...
- Hematologic disorders associated with hepatitis C virus infection and their managementDouglas T Dieterich
Department of Medicine, Mount Sinai Medical Center, New York, New York, USA
Clin Infect Dis 37:533-41. 2003..This review highlights the pharmacology, risks, and benefits of recombinant hematopoietic growth factor therapy in HCV-infected patients...
- The HIV/HCV-coinfected patient and new treatment optionsMarie Louise C Vachon
Division of Infectious Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
Clin Liver Dis 15:585-96. 2011..This article reviews the latest predictive factors of response to HCV treatment with the current standard of care in HIV-coinfected patients, and new treatment options...
- Toxicity of non-nucleoside analogue reverse transcriptase inhibitorsNickolas Kontorinis
Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
Semin Liver Dis 23:173-82. 2003..Close monitoring of transaminases is suggested in all patients commencing HAART, especially those with preexisting liver disease and coinfection with viral hepatitis...
- Clinical factors that predict noncirrhotic portal hypertension in HIV-infected patients: a proposed diagnostic algorithmNeil D Parikh
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
J Infect Dis 209:734-8. 2014..Using these easily available clinical parameters, we developed an algorithm for early diagnosis of NCPH in HIV. ..
- Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapyAndrea D Branch
Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA
Clin Infect Dis 55:137-44. 2012....
- The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIVThomas D Schiano
Division of Liver Diseases, Department of Medicine, The Mount Sinai Medical Center, New York, NY, USA
Virchows Arch 458:231-5. 2011..This case demonstrates the development of HPS resulting from a drug-induced microvascular injury. The paired biopsies demonstrate that the initial vascular injury may disappear but that the portal hypertension and HPS progress...
- Human immunodeficiency virus and the liver: lessons learned and still to be learnedDouglas T Dieterich
Department of Gastroenterology, New York University School of Medicine, New York, New York 10001, USA
Semin Liver Dis 23:107-14. 2003
- MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathyValérie Martel-Laferrière
Department of Medicine, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, One Gustave L, Levy Place, New York, NY 10029, USA
BMC Gastroenterol 14:185. 2014..Hepatic encephalopathy (HE) represents a significant burden to the healthcare system. The aim of this study was to determine factors influencing the hospital length of stay among patients hospitalized with HE...
- Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapyJames F Crismale
Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Liver Int 34:1018-24. 2014..Adding telaprevir to pegylated-interferon and ribavirin increased both response rates and side effects of hepatitis C virus (HCV) treatment. We identified variables associated with severe anaemia during telaprevir-based triple therapy...
- HIV-hepatitis C virus co-infection in the era of direct-acting antiviralsKian Bichoupan
Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA
Curr HIV/AIDS Rep 11:241-9. 2014....
- Pegylated-IFNα2a for HIV/hepatitis C virus coinfected patients: out with the old, in with the newKian Bichoupan
Icahn School of Medicine, New York, NY, USA
Expert Opin Biol Ther 14:1369-78. 2014..Liver disease is a major burden in patients co-infected with HIV and hepatitis C virus (HCV). From the time of its approval, pegylated-IFNα-2a (pegIFN-α2a) has played a major role in treatment of HCV in HIV/HCV co-infection...
- Interferon-free regimens for hepatitis C: combine and conquerValérie Martel-Laferrière
Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY, 10129, USA
BioDrugs 28:161-9. 2014..This paper reviews the interferon-free regimens currently in phase II or III for which sustained virologic response data are available and discusses the successes and potential pitfalls of these regimens. ..
- Hepatitis C in HIV-infected patients: impact of direct-acting antiviralsKian Bichoupan
Icahn School of Medicine at the Mount Sinai School of Medicine, New York, USA
Drugs 74:951-61. 2014..New results investigating telaprevir and boceprevir are also discussed as they are relevant for locations where new DAAs are not available. The impact future interferon-free therapies may have on co-infected patients is also discussed...
- Genetic analysis of interferon induced thyroiditis (IIT): evidence for a key role for MHC and apoptosis related genes and pathwaysAlia Hasham
Division of Endocrinology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
J Autoimmun 44:61-70. 2013..1), HLA (6p21.3), and TAP1 (6p21.3) that may be involved in the pathogenesis of IIT. Immune-regulation and apoptosis emerged as the predominant mechanisms underlying the etiology of IIT. ..
- Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitorsRon Palmon
Department of Medicine, New York University School of Medicine, New York City, New York, USA
J Acquir Immune Defic Syndr 29:340-5. 2002..HBV or HCV was not associated with a significant increase in AST or ALT elevations. We conclude that NNRTIs are relatively free from hepatotoxicity in this population, despite the presence of coinfection with HBV or HCV...
- Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infectionJohn Hornberger
The SPHERE Institute Acumen, LLC, Burlingame, CA 94010, USA
J Clin Virol 36:283-91. 2006..The cost-effectiveness of treating these patients with peginterferon alfa-2a/ribavirin has yet to be explored from a US societal perspective...
- Acute HIV seroconversion in a patient receiving pegylated interferon for treatment of hepatitis CElana Maser
University of Toronto, Toronto, Canada
AIDS Read 13:279-80, 287. 2003..However, the diagnosis of HIV infection during treatment of hepatitis C has not been reported. We present a case of acute HIV seroconversion in a patient who was not responding to interferon therapy for treatment of hepatitis C...
- Editorial comment: liver disease in the HIV-infected patient--the courage to treatDouglas T Dieterich
AIDS Read 13:500-1. 2003
- Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trialMark S Sulkowski
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
J Acquir Immune Defic Syndr 35:464-72. 2004..In conclusion, SVR was achieved in 19% of HIV/HCV coinfected subjects treated with daily IFN plus RBV, but the effectiveness of therapy was substantially diminished by relatively high rates of treatment-related toxicity...
- Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled studyNezam H Afdhal
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Gastroenterology 126:1302-11. 2004..This study assessed whether epoetin alfa could maintain RBV dose, improve quality of life (QOL), and increase hemoglobin (Hb) in anemic HCV-infected patients...
- Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patientsFrancesca J Torriani
Department of Medicine, Division of Infectious Diseases, University of California, San Diego, Antiviral Research Center, CA 92103, USA
N Engl J Med 351:438-50. 2004....
- The challenge of hepatitis C and HIV co-infectionDamaris C Carriero
Division of Liver Diseases, Mount Sinai School of Medicine, Manhattan, NY, USA
Body Posit 18:8-12, 15-7. 2005
- Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trialMark S Sulkowski
J Acquir Immune Defic Syndr 39:504-6. 2005
- Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapyPaul J Pockros
Scripps Clinic, La Jolla, CA 92037, USA
Hepatology 40:1450-8. 2004..Hb improvement was an independent predictor of HRQL improvement in these patients. In conclusion, epoetin alfa provided clinically significant HRQL improvement in HCV-infected patients receiving IFN/RBV therapy...
- Treatment of acute hepatitis C in an HIV-positive man with pegylated interferon and ribavirin for 24 weeksNila Rafiq
AIDS Read 17:561-4. 2007..After 4 weeks of therapy, the patient's HCV RNA level became undetectable and remained undetectable 1 year after the 24-week treatment course...
- Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfectionMilos Opravil
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
J Acquir Immune Defic Syndr 47:36-49. 2008..The impact of baseline CD4 status on hepatitis C virus (HCV) treatment response among patients with HIV/HCV coinfection was investigated using data from a randomized study of peginterferon alfa-2a (40KD) + ribavirin (Peg-IFN/RBV)...
- Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infectionGregory J Dore
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
AIDS 21:1555-9. 2007..To identify baseline characteristics predictive of a sustained virological response (SVR) in patients with HIV-hepatitis C virus (HCV) co-infection treated with interferon-based therapy...
- Editorial comment: a tale of two virusesDouglas T Dieterich
AIDS Read 12:448-9. 2002
- A treatment algorithm for the management of chronic hepatitis B virus infection in the United StatesEmmet B Keeffe
Stanford University Medical Center, 750 Welch Road, Suite 210, Palo Alto, California 94304 1509, USA
Clin Gastroenterol Hepatol 2:87-106. 2004....
- Hepatitis C management in HIV infection--where is the controversy?Douglas T Dieterich
AIDS Read 12:22-3. 2002
- Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategiesAftab Ala
AIDS Read 14:134-5. 2004
- Chronic hepatitis B: preventing, detecting, and managing viral resistanceEmmet B Keeffe
Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
Clin Gastroenterol Hepatol 6:268-74. 2008..Despite the substantial advances in treatment made to date, new agents with novel viral targets will be needed for patients who ultimately may fail second- or third-line therapy...
- Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy studyMaribel Rodriguez-Torres
Fundacion de Investigacion de Diego, Avenida De Diego 359, Santurce, PR 09909, USA
J Hepatol 48:756-64. 2008..A large population of patients from the AIDS Pegasys Ribavirin International Co-infection Trial (APRICOT) had paired liver biopsies interpreted and graded for steatosis along with lipid measurements and anthropometric data...
- Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter studyNorbert Brau
Bronx Veterans Affairs VA Medical Center, Infectious Disease Section 111F, 130 West Kingsbridge Road, Bronx, NY 10468, USA
J Hepatol 47:527-37. 2007..HIV-infected patients now live longer and often have complications of liver disease, especially with hepatitis B or C virus coinfection. Limited data are available on those with hepatocellular carcinoma (HCC)...
- Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis BEmmet B Keeffe
Stanford University School of Medicine, Stanford, California 94304 1509, USA
Clin Gastroenterol Hepatol 5:890-7. 2007..Future studies of the use of the roadmap concept in improving outcomes of chronic hepatitis B are warranted...
- A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an updateEmmet B Keeffe
Division of Gastroenterology and Hepatology, Stanford University Medical Center, CA 94304, USA
Clin Gastroenterol Hepatol 4:936-62. 2006..Issues for consideration include efficacy, safety, incidence of resistance, method of administration, and cost...
- Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitisJohn H Kempen
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Ophthalmology 113:684-94. 2006..To evaluate the prevalence of and risk factors for immune recovery uveitis (IRU) in eyes of patients with AIDS and cytomegalovirus (CMV) retinitis...